IDEAYA Corp (IDYA) - Market Cap to Net Income Ratio

The IFRS P/E ratio for IDEAYA Biosciences (IDYA) on GURU.Markets shows a trend where the parameter has stabilized at -7.60. This trend is driven by the implementation of bioethics and environmental standards in production. Developments are based on pairing precision drugs with biomarkers to personalize treatment. Meanwhile, the scaling of tests is increasing costs, while future profitability relies on potential licensing contracts.

IDYA ideayabio.com: Price to Earnings Ratio in the range 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for IDEAYA Bio (IDYA)

- market price and analyst price targets:

Market Price ideayabio.com|IDYA - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization IDEAYA Biosciences, Inc.|IDYA - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Net Asset Value per Share IDEAYA Biosciences|IDYA - Company Net Assets|Market Value to Book Value ideayabio.com|IDYA - Cumulative Company Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

IDYA - Net Income|Future Net Profit IDEAYA Biosciences|IDYA - P/E Multiple|Projected Price to Earnings Ratio IDEAYA Biosciences Inc|IDYA - PEG Multiple|Enterprise Value to Operating Income Before Depreciation IDEAYA Biosciences, Inc.|IDYA - Operating profit before deduction of amortization|Earnings per share for the trailing year IDEAYA Biosciences|IDYA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months ideayabio.com|IDYA - Earnings growth in current year|Expected earnings per share trend next year IDEAYA Biosciences

Comprehensive company analysis:ideayabio.com - IDYA

To separate fundamental value from speculative noise, an investor analyzes the ratio of market price to actual net profit, which allows for an assessment of real capital efficiency. In the context of IDEAYA Biosciences (IDYA), which invests in retaining elite oncologists through option programs, this price-to-earnings ratio reveals the extent to which market expectations for targeted therapy align with the issuer's current financial stability.

Key competitors